Arthrospira platensis non-parenteral therapeutic delivery platform
AssigneeLumen Bioscience, Inc.
InventorsJames Roberts, Michael Tasch, Mesfin Gewe, Benjamin Jester, Tracy Saveria
Life of this patent
Estimating the term…
Abstract
The present disclosure provides non-parenteral compositions comprising a recombinant Spirulina comprising at least one exogenous therapeutic. Compositions of the present disclosure can be used as vaccines and/or therapeutic drugs. The present disclosure also provides methods of making recombinant Spirulina comprising at least one exogenous therapeutic, and methods of treatment.
Claims20
An oral composition comprising three recombinant Spirulina, wherein each of the three recombinant Spirulina encapsulates a different VHH molecule or binding fragment thereof that binds to a C. difficile toxin, and wherein the VHH molecules or binding fragments thereof comprise:
- a) amino acid residues 26-32 (CDR1), 52-57 (CDR2), and 98-116 (CDR3) of SEQ ID NO:
- 5;
- b) amino acid residues 26-32 (CDR1), 52-56 (CDR2), and 98-100 (CDR3) of SEQ ID NO:
- 6;
- and
- c) amino acid residues 26-32 (CDR1), 52-56 (CDR2), and 98-105 (CDR3) of SEQ ID NO:
- 13.
An oral composition comprising:
- i) three non-living recombinant Spirulina, wherein each of the three non-living recombinant Spirulina encapsulates a different VHH molecule or binding fragment thereof that binds to a C. difficile toxin, wherein the VHH molecules or binding fragments thereof comprise:
- a) amino acid residues 26-32 (CDR1), 52-57 (CDR2), and 98-116 (CDR3) of SEQ ID NO:
- 5;
- b) amino acid residues 26-32 (CDR1), 52-56 (CDR2), and 98-100 (CDR3) of SEQ ID NO:
- 6;
- and
- c) amino acid residues 26-32 (CDR1), 52-56 (CDR2), and 98-105 (CDR3) of SEQ ID NO:
- 13;
- and
- ii) a lysin.
Dependencies are inferred from the claim text.